AstraZeneca Advances Oral GLP-1 RA Elecoglipron Asset into Phase III Programme Following Robust Phase IIb Results
AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to 11.8% weight loss and a 1.9% reduction in HbA1c.
Johnson & Johnson Firefly Bio Acquisition: JNJ Acquires Firelink DAC Platform for $1 Billion
Johnson & Johnson has announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash to secure its novel Firelinkâ„¢ degrader antibody conjugate platform.
Novo Nordisk Zenagamtide Drives Major HbA1c and Weight Reductions at ADA 2026
At the ADA 2026 Scientific Sessions, Novo Nordisk unveiled Phase 2 data for zenagamtide (amycretin), demonstrating exceptional blood sugar control and weight loss in type 2 diabetes.
Gilead Sciences Applauds Collaborative South African Launch of Lenacapavir HIV Prevention
Gilead Sciences has commended the leadership of the South African Government and the Global Fund for accelerating early access to its long-acting HIV prevention medication, lenacapavir.
Johnson & Johnson Announces Breakthrough Results: Nipocalimab SLE Phase 2 Study Demonstrates Significant Reduction in Systemic Lupus Erythematosus Activity
Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.
Novo Nordisk Launches Wegovy Pill in the UAE
Novo Nordisk has expanded global access to obesity care by launching the once-daily Wegovy pill in the United Arab Emirates, offering a non-injectable alternative with a 17% mean weight loss and MACE risk reduction.
AstraZeneca Camizestrant Breast Cancer Treatment Delays Disease Progression by 55%
The Phase III SERENA-6 trial reveals that switching to AstraZeneca Camizestrant Breast Cancer Treatment yields a 55% reduction in disease progression risk for advanced HR-positive breast cancer patients with emergent ESR1 mutations.
FDA Accepts Priority Review for Roche Giredestrant in Early-Stage Breast Cancer
Roche announces FDA Priority Review for giredestrant, the first oral SERD showing positive phase III results in the curative, adjuvant setting for ER-positive early breast cancer.
Roche Obesity Portfolio Forges Ahead as Enicepatide and Petrelintide Show Landmark Phase II Efficacy
Roche announces groundbreaking Phase II data for enicepatide and petrelintide ahead of the ADA 2026 Scientific Sessions, positioning its pipeline for best-in-class weight loss and advanced combination therapies.
New 144-Week Data Affirms Superiority of Novartis Scemblix CML Treatment
Novartis announced impressive 144-week data for its groundbreaking STAMP inhibitor, showcasing widening superior molecular response rates and better tolerability compared to standard TKIs in newly diagnosed CML patients.